EG-501 for Cognitive Impairment in Neuropsychiatric SLE (NPSLE): Efficacy and Safety Study

NCT07281105 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

131

Enrollment

INDUSTRY

Sponsor class

Conditions

Neuropsychiatric Systemic Lupus Erythematosus
Systemic Lupus Erythematosus (SLE)
Cognitive Impairment

Interventions

DRUG: Placebo
DRUG: EG-501

Sponsor

Evergreen Therapeutics, Inc.

Collaborators

[object Object]